Cost‐Utility Analysis of Low‐Dose Pioglitazone in a Population With Prediabetes and a History of Stroke or Transient Ischemic Attack
Holding across a wide range of values in modeling parameters, low-dose pioglitazone is found as the dominant strategy versus a placebo.
Authors
- J. David Spence (ORCID: https://orcid.org/0000-0001-7478-1098)
- Jean‐Éric Tarride (ORCID: https://orcid.org/0000-0003-2913-7580)
- Fei Yuan (ORCID: https://orcid.org/0000-0001-5408-8261)
Institutions
- Western University (CA)
- Population Health Research Institute (CA)
- Programs for Assessment of Technology in Health Research Institute (CA)
- Impact (CA)
- St. Joseph’s Healthcare Hamilton (CA)
- McMaster University (CA)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1161/jaha.123.034531
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.07